Psychiatry and Neurology, Neurology · Tyler, TX
NPI
1134128176
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
6
Hospital affiliations
11937 US Highway 271
Tyler, TX, 75708
Phone (903) 877-7177
Groups this clinician bills Medicare through
Medicare paid, 2024
$114K
1,709 services
Medicare patients, 2024
522
Average age 75
Drug cost, 2024
$1.5M
3,905 prescriptions
Company payments, 2025
$1,487
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert L Boyne was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 659 times for 452 patients. In total Robert L Boyne billed 1,709 services in 32 codes, and Medicare paid $114K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-17.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 659 | 452 | $11.07 | $7,294 |
| 99214 Office E&M - Established | Office | 340 | 235 | $85.55 | $29K |
| 99213 Office E&M - Established | Office | 256 | 220 | $56.66 | $15K |
| 99205 Office E&M - New | Office | 224 | 224 | $144.32 | $32K |
| 95816 Neurologic | Office | 55 | 54 | $265.97 | $15K |
| 95886 Electrical Nerve Conductivity | Office | 36 | 21 | $63.51 | $2,286 |
| 99215 Office E&M - Established | Office | 28 | 26 | $120.25 | $3,367 |
| 95911 Electrical Nerve Conductivity | Office | 12 | 12 | $145.10 | $1,741 |
By year: 2022 $157K for 1,690 services; 2023 $137K for 1,401 services; 2024 $114K for 1,709 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert L Boyne prescribed most often to Medicare patients was Donepezil Hcl, with 560 prescriptions and refills. In total Robert L Boyne wrote 3,905 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Donepezil Hcl Generic | 560 | 880 | 126 | $5,967 |
| Gabapentin Generic | 335 | 470 | 67 | $7,230 |
| Pregabalin Generic | 211 | 233 | 34 | $3,399 |
| Memantine Hcl Generic | 173 | 242 | 28 | $1,860 |
| Lorazepam Generic | 148 | 158 | 34 | $522 |
| Levetiracetam Generic | 145 | 245 | 29 | $4,096 |
| Topiramate Generic | 132 | 219 | 25 | $711 |
| Tramadol Hcl Generic | 104 | 113 | 21 | $479 |
| Carisoprodol Generic | 96 | 102 | 17 | $621 |
| Primidone Generic | 90 | 155 | 17 | $1,186 |
| Duloxetine Hcl Generic | 84 | 126 | 15 | $2,259 |
| Clonazepam Generic | 81 | 95 | 15 | $589 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 81 | 125 | 16 | $1,733 |
| Acetaminophen-Codeine Acetaminophen With Codeine | 73 | 73 | 18 | $790 |
| Diazepam Generic | 70 | 73 | 17 | $1,574 |
Brand drugs: 378 claims; generic drugs: 3,509 claims; opioid claims: 177.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert L Boyne $1,487 ($1,487 in general payments such as food, travel and fees) from 19 companies. The largest payer was Abbvie Inc. with $329.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 39 | $329 |
| Impel Pharmaceuticals LLC | 7 | $150 |
| Eisai Inc. 4523.T | 3 | $150 |
| Pfizer Inc. PFE | 14 | $140 |
| Teva Pharmaceuticals USA, Inc. TEVA | 6 | $136 |
| Biogen, Inc. BIIB | 4 | $87.53 |
| Grifols USA, LLC | 3 | $77.92 |
| Genentech USA, Inc. ROG.SW | 3 | $67.83 |
| Axsome Therapeutics, Inc. AXSM | 3 | $60.33 |
| Averitas Pharma Inc. | 2 | $51.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.